News

08.30.2022  |  News

Despite industry-wide stock slump, Mass. biotech startups raised $5.1 billion in the first half of 2022

From Boston Globe

08.24.2022  |  News

BRIEF—bluebird bio exec flies nest to join Tessera Therapeutics

From The Pharma Letter

08.24.2022  |  News

Bluebird exec spreads wings, heads over to Tessera for 'irresistible opportunity'

From Fierce Biotech

08.24.2022  |  News

Bluebird’s regulatory chief departs two days after historic gene therapy nod to join Flagship’s Tessera

From Endpoints News

08.24.2022  |  News

Bluebird's Eggimann joins Tessera team

From BioCentury

08.24.2022  |  News

Tessera Therapeutics Expands Leadership and Board

From Business Wire

08.03.2022  |  News

Biomanufacturing Parallels the Semiconductor Chip Revolution

From Genetic Engineering & Biotechnology News

07.07.2022  |  News

Non-CRISPR Gene Editing Platforms Make the Cut … or Avoid Making It

From Genetic Engineering & Biotechnology News

06.02.2022  |  News

Michael Severino trades in AbbVie perch for CEO role at Flagship’s gene medicines biotech Tessera

From Endpoints News

06.02.2022  |  News

From Big Pharma to little Tessera, Michael Severino rewrites his next chapter as CEO of Flagship biotech

From Fierce Biotech

06.02.2022  |  News

Former AbbVie executive Severino joins Flagship-backed startup as CEO

From BioPharma Dive

06.02.2022  |  News

Michael Severino, M.D., Joins Flagship Pioneering-Founded Tessera Therapeutics as Chief Executive Officer

From Business Wire

04.20.2022  |  News

Tessera snags $300M+ for gene writing tech

From PitchBook

04.20.2022  |  News

Flagship-backed 'gene-writing' startup Tessera raises $300M

From Boston Business Journal

04.19.2022  |  News

Tessera Therapeutics Announces Over $300M Series C Financing to Advance its GENE WRITING Platform

From Business Wire

04.19.2022  |  News

Finance Watch: Tessera Secures $300m-Plus To Write New Genes

From Scrip

04.19.2022  |  News

Flagship-founded Tessera fuels up with $300M 'to go on a really big adventure' in gene editing

From Endpoints News

04.19.2022  |  News

Flagship-Backed Tessera Raises $300 Million for Gene-Fixing Tech

From Bloomberg

04.19.2022  |  News

April 19 Quick Takes: Flagship-founded Tessera raises $300M from broad syndicate

From BioCentury

04.19.2022  |  News

Tessera Therapeutics stacks up more than $300M in series C funds to bolster new gene-editing platforms

From Fierce Biotech

02.14.2022  |  News

Navigating Recruitment and Hiring Amid ‘The Great Resignation’: Bec Lillie, Chief Human Resources Officer, Tessera

From Pharmaceutical Executive

01.28.2022  |  News

These gene-editing startups are aiming to solve one of CRISPR's biggest problems. Here's how they could upend biotech in 2022

From Business Insider

01.05.2022  |  News

Novel Gene Editing Systems Come Into Their Own

From Genetic Engineering & Biotechnology News

01.05.2022  |  News

Scientists Race to Make Really Big Changes to Your Genes

From Barron's